Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diazepinomicin - Amo Pharma

Next Previous
X
Search
Drug Profile

Diazepinomicin - Amo Pharma

Alternative Names: AMO 01; BU-4664L; ECO 04601; ECO 4601; TLN 4601

Latest Information Update: 03 Jul 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ecopia BioSciences
  • Developer AMO Pharma; BELLUS Health
  • Class Alkaloids; Antineoplastics; Benzodiazepinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; Ras protein inhibitors; TSPO protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Telomeric 22q13 Monosomy Syndrome
  • No development reported Fragile X syndrome
  • Discontinued Glioblastoma

Most Recent Events

  • 28 Jun 2023 BELLUS Health has been acquired by GSK
  • 29 Nov 2022 Diazepinomicinis still in phase-II trials for Telomerase-22q13 monosomy syndrome in USA (Amo Pharma pipeline; November 2022)
  • 28 Jul 2019 No recent reports of development identified for phase-I development in Fragile-X-syndrome in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top